More on circumcision.

P. Fleiss

Abstract:

What problem does this paper attempt to address?

Erratum: CP-Violating Effect of the Th Nuclear Magnetic Quadrupole Moment: Accurate Many-Body Study of ThO [Phys. Rev. Lett. 113, 263006 (2014)].

L. Skripnikov,A. Petrov,A. Titov,V. Flambaum

DOI: https://doi.org/10.1103/PhysRevLett.115.259901

IF: 8.6

2015-12-15

Physical Review Letters

Abstract:After the publication of this Letter, we have found an error in our computer code for the calculation of the matrix elements of the operator corresponding to the molecular parameterWM of the interaction of the nuclear magnetic quadrupole moment with electrons in heavy-atom molecules. This results in extra factor of 1.5 in the final value of WM. Therefore, the last paragraph on page 263006-3 should read as follows: The final calculated value of WM is 1.10ð8Þ × 10 Hz=ðe cm2Þ. The theoretical uncertainty was estimated with a procedure similar to that given in Ref. [1]. We have found that the effect of spin polarization of subvalence closed shells contributes aboutþ0.06 × 10 Hz=ðe cm2Þ, while the spin-orbit interaction of the valence and subvalence electrons contribute −0.05 × 10 Hz=ðe cm2Þ. The result of the earlier performed “semiempirical” estimate [2] 1.9 × 10 Hz=ðe cm2Þ is in reasonable agreement with the current ab initio calculations. Equations (15) and (16) should read
Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?

Tsukasa Okiyoneda,Christian Borgo,Valentina Bosello Travain,Nicoletta Pedemonte,Mauro Salvi

DOI: https://doi.org/10.1007/s00018-024-05295-z

IF: 8

2024-06-20

Cellular and Molecular Life Sciences

Abstract:Cystic Fibrosis (CF) is a genetic disease caused by mutations in CFTR gene expressing the anion selective channel CFTR located at the plasma membrane of different epithelial cells. The most commonly investigated variant causing CF is F508del. This mutation leads to structural defects in the CFTR protein, which are recognized by the endoplasmic reticulum (ER) quality control system. As a result, the protein is retained in the ER and degraded via the ubiquitin–proteasome pathway. Although blocking ubiquitination to stabilize the CFTR protein has long been considered a potential pharmacological approach in CF, progress in this area has been relatively slow. Currently, no compounds targeting this pathway have entered clinical trials for CF. On the other hand, the emergence of Orkambi initially, and notably the subsequent introduction of Trikafta/Kaftrio, have demonstrated the effectiveness of molecular chaperone-based therapies for patients carrying the F508del variant and even showed efficacy against other variants. These treatments directly target the CFTR variant protein without interfering with cell signaling pathways. This review discusses the limits and potential future of targeting protein ubiquitination in CF.

cell biology,biochemistry & molecular biology
Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1

K. Arora,C. C. Moon,W. Zhang,H. Penmatsa,A. Ren,S. Yarlagadda,C. Sinha,A. Naren

DOI: https://doi.org/10.1096/fasebj.27.1_supplement.553.4

2013-01-01

Abstract:Cystic fibrosis (CF) is a lethal genetic disease and warrants effective therapeutic interventions. Preclinical studies screened CF‐correctors based on their ability to partially correct the processing defects of ΔF508 mutation of cystic fibrosis transmembrane conductance regulator (CFTR), the most common CF causing mutation. The CF‐corrector VX‐809 underwent Phase II trials in combination with VX‐770 or Ivacaftor and was shown to significantly improve lung function in CF patients. In this study, we demonstrate the significance of protein‐protein interaction in enhancing the stability of mutant channel protein at the plasma membrane. We show that VX‐809 partially stabilizes ΔF508‐CFTR interaction with scaffolding protein Na+/H+ exchanger regulatory factor 1 (NHERF1) at the plasma membrane. We demonstrate in cystic fibrosis bronchial epithelial cells that VX‐809 increases half‐life of ΔF508 CFTR at the plasma membrane by potentiating its otherwise weak interaction with NHERF1. Single particle tracking analysis further strengthens our observation as VX‐809 restricts the mobility of ΔF508‐CFTR at the plasma membrane while the effect is mitigated in ΔF508 CFTR His10 (lacks the PDZ motif and hence the ability to interact with NHERF1). Therefore, our studies demonstrate the importance of macromolecular complex in rescuing mutant CFTR to the plasma membrane and will further help device newer generation of more effective CF‐correctors.
Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators

Roberto Sabbadini,Emanuela Pesce,Alice Parodi,Eleonora Mustorgi,Santina Bruzzone,Nicoletta Pedemonte,Monica Casale,Enrico Millo,Elena Cichero

DOI: https://doi.org/10.3390/ph14121296

IF: 4.6

2021-12-12

Pharmaceuticals

Abstract:Cystic fibrosis (CF) is caused by different mutations related to the cystic fibrosis transmembrane regulator protein (CFTR), with F508del being the most common. Pioneering the development of CFTR modulators, thanks to the development of effective correctors or potentiators, more recent studies deeply encouraged the administration of triple combination therapeutics. However, combinations of molecules interacting with other proteins involved in functionality of the CFTR channel recently arose as a promising approach to address a large rescue of F508del-CFTR. In this context, the design of compounds properly targeting the molecular chaperone Hsp70, such as the allosteric inhibitor MKT-077, proved to be effective for the development of indirect CFTR modulators, endowed with ability to amplify the accumulation of the rescued protein. Herein we performed structure-based studies of a number of allosteric HSP70 inhibitors, considering the recent X-ray crystallographic structure of the human enzyme. This allowed us to point out the main interaction supporting the binding mode of MKT-077, as well as of the related analogues. In particular, cation-π and π–π stacking with the conserve residue Tyr175 deeply stabilized inhibitor binding at the HSP70 cavity. Molecular docking studies had been followed by QSAR analysis and then by virtual screening of aminoaryl thiazoles (I–IIIa) as putative HSP70 inhibitors. Their effectiveness as CFTR modulators has been verified by biological assays, in combination with VX-809, whose positive results confirmed the reliability of the whole applied computational method. Along with this, the “in-silico” prediction of absorption, distribution, metabolism, and excretion (ADME) properties highlighted, once more, that AATs may represent a chemical class to be further investigated for the rational design of novel combination of compounds for CF treatment.

pharmacology & pharmacy,chemistry, medicinal
CFTR structures bound to ETI components predict rare mutation response to modulator combinations

Noemie Stanleigh,Michal Gur,Michal Shteinberg,Aryeh Weiss,Naama Sebbag-Sznajder,Deborah Duran,Myriam Grunewald,Liron Birimberg-Schwartz,Ronen Bar-Yosef,Jeffrey M Beekman,Eitan Kerem,Batsheva Kerem

DOI: https://doi.org/10.1101/2024.10.12.24314979

2024-10-16

Abstract:Background: CFTR protein structures bound to each of Elexacaftor/Tezacaftor/Ivacaftor (ETI) were recently established. We aimed to use this data to predict and assess responses to ETI and each of its components in intestinal organoids derived from patients carrying rare CFTR mutations, not yet approved for ETI, based on their mutation location within the CFTR structure. Methods: Organoids were generated from six patients carrying the Q1100P and/or K163E alleles, not receiving ETI. Measurements of the response to ETI or combination of its components were performed in 3D-organoids by forskolin-induced swelling (FIS) and in 2D-monolayers by short-circuit currents (Isc). Based on these results, patients initiated off-label ETI treatment. Clinical data before and after treatment were collected. Results: VX-445 binds amino acids flanking Q1100P and VX-661 binds near the TM2-ICL1 boundary, where K163E is located. Thus, each modulator was predicted to contribute to the correction of one mutation. Functional measurements (FIS and Isc) indeed showed that Q1100P responded to VX-445 alone, and K163E to VX-661 alone. Unexpectedly, VX-445 had a dramatic effect on K163E function. Both mutations achieved clinically significant CFTR activity levels with VX-661+VX-445, without benefit from VX-770. Following these results ETI was initiated, resulting in significant and sustained clinical improvements, in all patients, in lung function (FEV1, LCI), BMI and sweat chloride. Conclusion: These results suggest that our structural approach can help predict response to the available modulators in patients carrying rare CFTR mutations. Furthermore, this approach allows for patient-specific optimization of modulator combinations, minimizing unnecessary exposure to ineffective treatments.
CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium

Clarissa Braccia,Josie A Christopher,Oliver M Crook,Lisa M Breckels,Rayner M L Queiroz,Nara Liessi,Valeria Tomati,Valeria Capurro,Tiziano Bandiera,Simona Baldassari,Nicoletta Pedemonte,Kathryn S Lilley,Andrea Armirotti

DOI: https://doi.org/10.3390/cells11121938

IF: 6

2022-06-16

Cells

Abstract:Background: Cystic Fibrosis (CF) is a genetic disorder affecting around 1 in every 3000 newborns. In the most common mutation, F508del, the defective anion channel, CFTR, is prevented from reaching the plasma membrane (PM) by the quality check control of the cell. Little is known about how CFTR pharmacological rescue impacts the cell proteome. Methods: We used high-resolution mass spectrometry, differential ultracentrifugation, machine learning and bioinformatics to investigate both changes in the expression and localization of the human bronchial epithelium CF model (F508del-CFTR CFBE41o-) proteome following treatment with VX-809 (Lumacaftor), a drug able to improve the trafficking of CFTR. Results: The data suggested no stark changes in protein expression, yet subtle localization changes of proteins of the mitochondria and peroxisomes were detected. We then used high-content confocal microscopy to further investigate the morphological and compositional changes of peroxisomes and mitochondria under these conditions, as well as in patient-derived primary cells. We profiled several thousand proteins and we determined the subcellular localization data for around 5000 of them using the LOPIT-DC spatial proteomics protocol. Conclusions: We observed that treatment with VX-809 induces extensive structural and functional remodelling of mitochondria and peroxisomes that resemble the phenotype of healthy cells. Our data suggest additional rescue mechanisms of VX-809 beyond the correction of aberrant folding of F508del-CFTR and subsequent trafficking to the PM.
High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing

Sacha Spelier,Eyleen de Poel,Georgia N Ithakisiou,Sylvia W F Suen,Marne C Hagemeijer,Danya Muilwijk,Annelotte M Vonk,Jesse E Brunsveld,Evelien Kruisselbrink,Cornelis K van der Ent,Jeffrey M Beekman

DOI: https://doi.org/10.1183/23120541.00495-2022

2023-01-30

Abstract:Background: Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent therapies enable effective restoration of CFTR function of the most common F508del CFTR mutation. This shifts the unmet clinical need towards people with rare CFTR mutations such as nonsense mutations, of which G542X and W1282X are most prevalent. CFTR function measurements in patient-derived cell-based assays played a critical role in preclinical drug development for CF and may play an important role to identify new drugs for people with rare CFTR mutations. Methods: Here, we miniaturised the previously described forskolin-induced swelling (FIS) assay in intestinal organoids from a 96-well to a 384-well plate screening format. Using this novel assay, we tested CFTR increasing potential of a 1400-compound Food and Drug Administration (FDA)-approved drug library in organoids from donors with W1282X/W1282X CFTR nonsense mutations. Results: The 384-well FIS assay demonstrated uniformity and robustness based on coefficient of variation and Z'-factor calculations. In the primary screen, CFTR induction was limited overall, yet interestingly, the top five compound combinations that increased CFTR function all contained at least one statin. In the secondary screen, we indeed verified that four out of the five statins (mevastatin, lovastatin, simvastatin and fluvastatin) increased CFTR function when combined with CFTR modulators. Statin-induced CFTR rescue was concentration-dependent and W1282X-specific. Conclusions: Future studies should focus on elucidating genotype specificity and mode-of-action of statins in more detail. This study exemplifies proof of principle of large-scale compound screening in a functional assay using patient-derived organoids.
DRUGS AND LIVER DISEASE

S. Sherlock

DOI: https://doi.org/10.1007/978-94-011-1994-8_15

Abstract:
Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the CFTR Gene

Anna Efremova,Yuliya Melyanovskaya,Maria Krasnova,Anna Voronkova,Diana Mokrousova,Elena Zhekaite,Nataliya Bulatenko,Oleg Makhnach,Tatiana Bukharova,Sergei Kutsev,Dmitry Goldshtein,Elena Kondratyeva

DOI: https://doi.org/10.3390/ijms251910424

IF: 5.6

2024-09-28

International Journal of Molecular Sciences

Abstract:Complex alleles of the CFTR gene complicate the diagnosis of cystic fibrosis (CF), the classification of its pathogenic variants, affect the clinical picture of the disease and can affect the efficiency of targeted drugs. The total frequency of complex allele [L467F;F508del] in the Russian population of patients with CF is 0.74%, and in patients with the F508del/F508del genotype, its frequency reaches 8%. This article presents multi-faceted study of the complex allele [L467F;F508del] in a cohort of patients with genotypes [L467F;F508del]/class I (c.3532_3535dup, c.1766+2T>C, W1310X, 712-1G>T), and data for a unique patient with the genotype [L467F;F508del]/[L467F;F508del]. Using the intestinal current measurement method, it was demonstrated the absence of CFTR function for [L467F;F508del]/class I and [L467F;F508del]/[L467F;F508del] genotypes. In intestinal organoids, it was shown that [L467F;F508del] in combination with class I variants and in the homozygotes abolishes the efficacy of both two-component (ivacaftor+lumacaftor; ivacaftor+tezacaftor) and three-component (ivacaftor+tezacaftor+elexacaftor) targeted drugs. When prescribing ivacaftor+tezacaftor+elexacaftor to three patients, they did not have a clinical effect after 6–12 months.

biochemistry & molecular biology,chemistry, multidisciplinary
Structure-based discovery of CFTR potentiators and inhibitors

Fangyu Liu,Anat Levit Kaplan,Jesper Levring,Jürgen Einsiedel,Stephanie Tiedt,Katharina Distler,Natalie S. Omattage,Ivan S. Kondratov,Yurii S. Moroz,Harlan L. Pietz,John J. Irwin,Peter Gmeiner,Brian K. Shoichet,Jue Chen

DOI: https://doi.org/10.1101/2023.09.09.557002

2024-03-11

Abstract:The cystic fibrosis transmembrane conductance regulator (CFTR) is a crucial ion channel whose loss of function leads to cystic fibrosis, while its hyperactivation leads to secretory diarrhea. Small molecules that improve CFTR folding (correctors) or function (potentiators) are clinically available. However, the only potentiator, ivacaftor, has suboptimal pharmacokinetics and inhibitors have yet to be clinically developed. Here we combine molecular docking, electrophysiology, cryo-EM, and medicinal chemistry to identify novel CFTR modulators. We docked ∼155 million molecules into the potentiator site on CFTR, synthesized 53 test ligands, and used structure-based optimization to identify candidate modulators. This approach uncovered novel mid-nanomolar potentiators as well as inhibitors that bind to the same allosteric site. These molecules represent potential leads for the development of more effective drugs for cystic fibrosis and secretory diarrhea, demonstrating the feasibility of large-scale docking for ion channel drug discovery.

Biophysics
A Lesson from a Study with the F508del-CFTR Mutant

Christian Borgo,Claudio D'Amore,Valeria Capurro,Valeria Tomati,Nicoletta Pedemonte,Valentina Bosello Bosello Travain,Mauro Salvi

DOI: https://doi.org/10.3390/ijms25042302

IF: 5.6

2024-02-15

International Journal of Molecular Sciences

Abstract:Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a selective anion channel expressed in the epithelium of various organs. The most frequent mutation is F508del. This mutation leads to a misfolded CFTR protein quickly degraded via ubiquitination in the endoplasmic reticulum. Although preventing ubiquitination stabilizes the protein, functionality is not restored due to impaired plasma membrane transport. However, inhibiting the ubiquitination process can improve the effectiveness of correctors which act as chemical chaperones, facilitating F508del CFTR trafficking to the plasma membrane. Previous studies indicate a crosstalk between SUMOylation and ubiquitination in the regulation of CFTR. In this study, we investigated the potential of inhibiting SUMOylation to increase the effects of correctors and enhance the rescue of the F508del mutant across various cell models. In the widely used CFBE41o-cell line expressing F508del-CFTR, inhibiting SUMOylation substantially boosted F508del expression, thereby increasing the efficacy of correctors. Interestingly, this outcome did not result from enhanced stability of the mutant channel, but rather from augmented cytomegalovirus (CMV) promoter-mediated gene expression of F508del-CFTR. Notably, CFTR regulated by endogenous promoters in multiple cell lines or patient cells was not influenced by SUMOylation inhibitors.

biochemistry & molecular biology,chemistry, multidisciplinary
Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Zhiwei Cai,Jia Liu,Hongyu Li,David N. Sheppard

DOI: https://doi.org/10.1038/aps.2011.71

IF: 7.169

2011-01-01

Acta Pharmacologica Sinica

Abstract:The mutation F508del is the commonest cause of the genetic disease cystic fibrosis (CF). CF disrupts the function of many organs in the body, most notably the lungs, by perturbing salt and water transport across epithelial surfaces. F508del causes harm in two principal ways. First, the mutation prevents delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) to its correct cellular location, the apical (lumen-facing) membrane of epithelial cells. Second, F508del perturbs the Cl(-) channel function of CFTR by disrupting channel gating. Here, we discuss the development of rational new therapies for CF that target F508del-CFTR. We highlight how structural studies provide new insight into the role of F508 in the regulation of channel gating by cycles of ATP binding and hydrolysis. We emphasize the use of high-throughput screening to identify lead compounds for therapy development. These compounds include CFTR correctors that restore the expression of F508del-CFTR at the apical membrane of epithelial cells and CFTR potentiators that rescue the F508del-CFTR gating defect. Initial results from clinical trials of CFTR correctors and potentiators augur well for the development of small molecule therapies that target the root cause of CF: mutations in CFTR.
[Mucoadhesive oral tablets--a modern dosage form with controlled drug release].

M. Dostálová,M. Rabišková

2000-03-01

Abstract:The review paper summarizes the principal pharmaceutical and medical information about the hitherto achieved results in the development of bioadhesive dosage form concentrating on mucoadhesive oral tablets. The site of administration of the tablets is the facial pocket. Due to specific properties of the mucous layer on the buccal mucosa and mucoadhesive polymers from which the tablets are manufactured, tablets adhere to the mucosa. The adhesion may take a certain period of time and during the whole period the active ingredient is gradually released. Absorption of the drug through the mucous membrane of the oral cavity has a number of advantages, in particular with respect to the stability of the drug. Various types of mucoadhesive tablets are being developed. The system releasing the drug only in one direction, i.e. direct to the mucosa, seems to be very advantageous. In the evaluation of mucoadhesive tablets, two parameters are of particular importance, the bioadhesive force and the rate of drug release. Oral mucoadhesive tablets can be employed in the treatment of both systemic and local diseases.
Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant

Muhammad Umer Khan,Azra Sakhawat,Raima Rehman,Abbas Haider Wali,Muhammad Usman Ghani,Areeba Akram,Muhammad Arshad Javed,Qurban Ali,Zhou Yu-Ming,Daoud Ali

DOI: https://doi.org/10.1186/s13568-024-01762-9

2024-09-09

AMB Express

Abstract:Cystic fibrosis transmembrane conductance regulator (CFTR) protein is an ion channel found in numerous epithelia and controls the flow of water and salt across the epithelium. The aim of our study to find natural compounds that can improve lung function for people with cystic fibrosis (CF) caused by the p.Gly628Arg (rs397508316) mutation of CFTR protein. The sequence of CFTR protein as a target structure was retrieved from UniProt and PDB database. The ligands that included Armepavine, Osthole, Curcumin, Plumbagine, Quercetin, and one Trikafta (R*) reference drug were screened out from PubChem database. Autodock vina software carried out docking, and binding energies between the drug and the target were included using docking-score. The following tools examined binding energy, interaction, stability, toxicity, and visualize protein-ligand complexes. The compounds having binding energies of -6.4, -5.1, -6.6, -5.1, and - 6.5 kcal/mol for Armepavine, Osthole, Curcumin, Plumbagine, Quercetin, and R*-drug, respectively with mutated CFTR (Gly628Arg) structure were chosen as the most promising ligands. The ligands bind to the mutated CFTR protein structure active sites in hydrophobic bonds, hydrogen bonds, and electrostatic interactions. According to ADMET analyses, the ligands Armepavine and Quercetin also displayed good pharmacokinetic and toxicity characteristics. An MD simulation for 200 ns was also established to ensure that Armepavine and Quercetin ligands attached to the target protein favorably and dynamically, and that protein-ligand complex stability was maintained. It is concluded that Armepavine and Quercetin have stronger capacity to inhibit the effect of mutated CFTR protein through improved trafficking and restoration of original function.
E-pharmacophore based virtual screening of potent lead molecules against Cystic Fibrosis: An in silico study

Sabareeswari Jeyaraman,Jeyanthi Sankar,Ling Shing Wong,Karthikeyan Muthusamy

DOI: https://doi.org/10.1016/j.compbiolchem.2024.108249

2024-10-12

Abstract:Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene, which encodes the CFTR protein. Currently, CF is a life-limiting illness that has a limited cure. The present study aimed to identify top leads against CFTR protein with F508del in comparison with Lumacaftor. In this study, a homology model of the NBD domain of CFTR protein was developed using the available NBD domain crystal structure. The protein model was refined through apo dynamics. Energy-optimized pharmacophore mapping was carried out to identify essential features for CFTR, resulting in a model with a hydrogen-bond donor, two hydrogen-bond acceptors, and three aromatic ring sites. A screening of a compound from the NPASS database using these DAARRR six-point-pharmacophore features led to the identification of potential ligands that could act against CFTR protein. Further studies such as ADME/T, molecular dynamics, MM_GBSA, and DFT were performed to identify the top-hit compound from the NPASS database. The compound Anguibactin (NPC41982) has been identified as a top lead that exhibits higher binding affinity and stability than the reference compound Lumacaftor, suggesting their potential to bind to the active site of the CFTR protein. These compounds could serve as starting points for the development of drug-like molecules for treating cystic fibrosis.
General practitioners and pathology testing

R. Vining,Paul R Mara

DOI: https://doi.org/10.5694/j.1326-5377.1998.tb141442.x

1998-06-01

Abstract:hosted the first international scientific meeting on heroin trials, reflecting growing international interest. A heroin trial will commence soon in the Netherlands, with trials under consideration in the UK, Germany, Spain, Austria and Canada. 10 Interestingly, police chiefs in 10 of the 12 largest cities in Germany have been pressing for such a trial. 10 The increasing interest in heroin trials is partly the result of authorities' growing acknowledgement of the failure of current policy. Were responses to illicit drugs to be decided entirely on the basis of evidence rather than fear and rhetoric, Australia would now be awaiting the results of the pilot stage of the ACT heroin trial. Demand for heroin is currently met by adulterated supplies of unknown concentration obtained from criminals. It seems probable that drug users and the general community would be better off if at least part of this demand were met by sterile heroin of known concentration prescribed by medical practitioners. Most doctors faced with a complex, chronic, relapsing-remitting disorder would prefer to choose from a range of effective treatments rather than rely on a single agent. The trials of new pharmacological agents are likely to extend and improve our therapeutic repertoire for Editorials
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors

Giada Righetti,Monica Casale,Nara Liessi,Bruno Tasso,Annalisa Salis,Michele Tonelli,Enrico Millo,Nicoletta Pedemonte,Paola Fossa,Elena Cichero

DOI: https://doi.org/10.3390/ijms21218084

IF: 5.6

2020-10-29

International Journal of Molecular Sciences

Abstract:Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. Different mutations involving the cystic fibrosis transmembrane regulator protein (CFTR) gene, which encodes the CFTR channel, are involved in CF. A number of life-prolonging therapies have been conceived and deeply investigated to combat this disease. Among them, the administration of the so-called CFTR modulators, such as correctors and potentiators, have led to quite beneficial effects. Recently, based on QSAR (quantitative structure activity relationship) studies, we reported the rational design and synthesis of compound 2, an aminoarylthiazole-VX-809 hybrid derivative exhibiting promising F508del-CFTR corrector ability. Herein, we explored the docking mode of the prototype VX-809 as well as of the aforementioned correctors in order to derive useful guidelines for the rational design of further analogues. In addition, we refined our previous QSAR analysis taking into account our first series of in-house hybrids. This allowed us to optimize the QSAR model based on the chemical structure and the potency profile of hybrids as F508del-CFTR correctors, identifying novel molecular descriptors explaining the SAR of the dataset. This study is expected to speed up the discovery process of novel potent CFTR modulators.
Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Yihong Fan,Corina Balut,Sara Alani,Ying Jia,Bo Liu,Xueqing Wang,Wenqing Gao,Tzyh-Chang Hwang,Douglas Cyr,Katja Conrath,Chris Tse,Ashvani K. Singh,Arlene M. Manelli,Andrew M. Swensen,Torben R. Neelands,Timothy A. Vortherms,Xenia B. Searle,Hong Y. Ren,Philip R. Kym

DOI: https://doi.org/10.1124/jpet.119.261800

2019-11-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease in Caucasians caused by pathogenic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR). Significant small molecule therapeutic advances over the past two decades have been made to target the defective CFTR protein and enhance its function. To address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in CF, two biomolecular activities are required, namely, correctors to increase the amount of properly folded F508delCFTR levels at the cell surface and potentiators to allow the effective opening, i.e., function of the F508delCFTR channel. Combined, these activities enhance chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance. To enhance clinical benefits to CF patients, a complementary triple combination therapy consisting of two corrector molecules, type 1 (C1) and type 2, with additive mechanisms along with a potentiator are being investigated in the clinic for maximum restoration of mutated CFTR function. We report the identification and in vitro biologic characterization of ABBV-2222/GLPG2222 (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid),—a novel, potent, and orally bioavailable C1 corrector developed by AbbVie-Galapagos and currently in clinical trials—which exhibits substantial improvements over the existing C1 correctors. This includes improvements in potency and drug-drug interaction (DDI) compared with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (VX-809, Lumacaftor) and improvements in potency and efficacy compared with 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (VX-661, Tezacaftor). ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value <10 nM.SIGNIFICANCE STATEMENTTo address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein. ABBV-2222/GLPG2222, which is currently in clinical trials, exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR and substantial improvements over the existing C1 correctors.

pharmacology & pharmacy
Shape evolution of Cu2O nanostructures via kinetic and thermodynamic controlled growth.

Choon Hwee Bernard Ng,W. Y. Fan

DOI: https://doi.org/10.1021/JP061835K

2006-09-23

Abstract:We report the shape evolution process of Cu(2)O nanocrystals upon slow oxidation of Cu under ambient conditions, yielding novel hexagonal and triangular platelike morphologies. The shape of the obtained nanocrystals evolves from hexagonal to triangular to octahedral; the growth patterns are governed by kinetically and thermodynamically controlled growth. Preferential adsorption of I(-) on {111} planes of Cu(2)O nanoparticles induced the selective crystal growth of metastable platelike structures with {111} faces as the basal planes. On aging, the growth process appeared to shift into the thermodynamic regime and the thermodynamically stable octahedral shape is obtained. The possible growth mechanisms were investigated by varying the synthetic conditions. The band gap of Cu(2)O nanooctahedrons was determined by the classical Tauc approach to be 2.24 eV, which is blue shifted with respect to the bulk Cu(2)O value (2.17 eV). Results suggest that the slow oxidation process and use of crystallographic selective surfactants are essential for the appearance of anisotropic metastable shapes. In general, surface energy control by surfactant molecules might provide a convenient channel for tailoring nanocrystal shapes of metal oxides.
Can two wrongs make a right? F508del-CFTR ion channel rescue by second-site mutations in its transmembrane domains

Stella Prins,Valentina Corradi,David N Sheppard,D Peter Tieleman,Paola Vergani

DOI: https://doi.org/10.1016/j.jbc.2022.101615

Abstract:Deletion of phenylalanine 508 (F508del) in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel is the most common cause of cystic fibrosis. The F508 residue is located on nucleotide-binding domain 1 (NBD1) in contact with the cytosolic extensions of the transmembrane helices, in particular intracellular loop 4 (ICL4). To investigate how absence of F508 at this interface impacts the CFTR protein, we carried out a mutagenesis scan of ICL4 by introducing second-site mutations at 11 positions in cis with F508del. Using an image-based fluorescence assay, we measured how each mutation affected membrane proximity and ion-channel function. The scan strongly validated the effectiveness of R1070W at rescuing F508del defects. Molecular dynamics simulations highlighted two features characterizing the ICL4/NBD1 interface of F508del/R1070W-CFTR: flexibility, with frequent transient formation of interdomain hydrogen bonds, and loosely stacked aromatic sidechains (F1068, R1070W, and F1074, mimicking F1068, F508, and F1074 in WT CFTR). F508del-CFTR displayed a distorted aromatic stack, with F1068 displaced toward the space vacated by F508, while in F508del/R1070F-CFTR, which largely retained F508del defects, R1070F could not form hydrogen bonds and the interface was less flexible. Other ICL4 second-site mutations which partially rescued F508del-CFTR included F1068M and F1074M. Methionine side chains allow hydrophobic interactions without the steric rigidity of aromatic rings, possibly conferring flexibility to accommodate the absence of F508 and retain a dynamic interface. These studies highlight how both hydrophobic interactions and conformational flexibility might be important at the ICL4/NBD1 interface, suggesting possible structural underpinnings of F508del-induced dysfunction.

More on circumcision.

Erratum: CP-Violating Effect of the Th Nuclear Magnetic Quadrupole Moment: Accurate Many-Body Study of ThO [Phys. Rev. Lett. 113, 263006 (2014)].

Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?

Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1

Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators

CFTR structures bound to ETI components predict rare mutation response to modulator combinations

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium

High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing

DRUGS AND LIVER DISEASE

Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the CFTR Gene

Structure-based discovery of CFTR potentiators and inhibitors

A Lesson from a Study with the F508del-CFTR Mutant

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

[Mucoadhesive oral tablets--a modern dosage form with controlled drug release].

Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant

E-pharmacophore based virtual screening of potent lead molecules against Cystic Fibrosis: An in silico study

General practitioners and pathology testing

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Shape evolution of Cu2O nanostructures via kinetic and thermodynamic controlled growth.

Can two wrongs make a right? F508del-CFTR ion channel rescue by second-site mutations in its transmembrane domains